SCHEMBL19974938

SCHEMBL19974938

CC(C(O)C(=O)NCC1CC1)N(C=O)c1ccc(Cl)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.47
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
PTGIR P43119 1/20 0.40
ALDH1A1 P00352 3/20 0.40
GAA P10253 2/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
F10 P00742 1/20 0.38
PRSS1 P07477 1/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
LMNA P02545 3/20 0.37
TSHR P16473 1/20 0.37
HPGD P15428 1/20 0.37
POLB P06746 3/20 0.36
CTDSP1 Q9GZU7 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
CNR1 P21554 1/20 0.36
CXCR3 P49682 1/20 0.35
P2RX3 P56373 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19975143 0.89 PTGIR (0.43) SMN1; SMN2NPC1RAB9APTGIRALDH1A1
SCHEMBL19975134 0.88 PTGIR (0.40) SMN1; SMN2NPC1RAB9APTGIRALDH1A1
SCHEMBL19975274 0.88 PTGIR (0.41) PTGIRALDH1A1GAAF10PRSS1
SCHEMBL19975062 0.86 ALDH1A1 (0.48) SMN1; SMN2PTGIRALDH1A1GAAL3MBTL1
SCHEMBL28315915 0.86 F10 (0.39) SMN1; SMN2ALDH1A1GAAL3MBTL1F10
SCHEMBL19974728 0.83 BCHE (0.42) SMN1; SMN2PTGIRALDH1A1GAAL3MBTL1
SCHEMBL19975353 0.83 BCHE (0.45) SMN1; SMN2ALDH1A1GAAL3MBTL1MEN1
SCHEMBL19974925 0.83 MEN1 (0.39) SMN1; SMN2PTGIRALDH1A1GAAL3MBTL1
SCHEMBL21176166 0.82 BCHE (0.46) SMN1; SMN2ALDH1A1GAAL3MBTL1MEN1
SCHEMBL28316641 0.81 SMN1; SMN2 (0.45) SMN1; SMN2NPC1RAB9APTGIRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220356148-A1 ANTIVIRAL COMPOUNDS HAPLOGEN GMBH (AT) 2022-11-10 US disclosed
US-11091428-B2 Antiviral compounds HAPLOGEN GMBH (AT) 2021-08-17 US disclosed
US-11091428-B2 Antiviral compounds HAPLOGEN GMBH (AT) 2021-08-17 US disclosed
US-20190225575-A1 ANTIVIRAL COMPOUNDS LUNIS CONSULTING GMBH (AT) 2019-07-25 US disclosed
US-20190225575-A1 ANTIVIRAL COMPOUNDS LUNIS CONSULTING GMBH (AT) 2019-07-25 US disclosed
EP-3512836-A1 ANTIVIRAL COMPOUNDS Haplogen GmbH (AT) 2019-07-24 EP disclosed
WO-2018050631-A1 ANTIVIRAL COMPOUNDS HAPLOGEN GMBH (AT) 2018-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190225575-A1 ANTIVIRAL COMPOUNDS PLA2G1B, PLA2G12A, PLA2G4C SMN1; SMN2 706/4885NPC1 753/4885RAB9A 1576/4885
US-20220356148-A1 ANTIVIRAL COMPOUNDS PLA2G12A, PLA2G1B, PLA2G4C SMN1; SMN2 1086/4885NPC1 1213/4885RAB9A 1334/4885
US-11091428-B2 Antiviral compounds PLA2G1B, PLA2G12A, PLA2G4C SMN1; SMN2 706/4885NPC1 753/4885RAB9A 1576/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.